Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

Martinez‐Zapata, Maria José; Salvador, Ignacio Cabeza del; Martí‐Carvajal, Arturo J; Pijoán, José Ignacio; Cordero, José Antonio; Ponomarev, Dmitry; Kernohan, Ashleigh; Solà, Iván; Virgili, Gianni

doi:10.1002/14651858.cd008721.pub3

Cited by 5 publications

(1 citation statement)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further studies confirmed that anti-VEGF therapy is non-inferior to PRP for the treatment of PDR [ 57 ]. Recent studies have shown benefit from intravitreal anti-VEGF alone in the treatment of PDR [ 58 , 59 , 60 ], although visual recovery is slower [ 61 ], and patients who are lost to follow-up after anti-VEGF alone are at risk of worse visual outcomes than if they had received laser treatment [ 62 ]. The combination of anti-VEGF and PRP is widely used clinically, but the benefit over PRP alone is modest [ 60 ].…”

Section: Diabetic Retinopathymentioning

confidence: 99%

Oxidative Stress and Its Regulation in Diabetic Retinopathy

Haydinger,

Oliver,

Ashander

et al. 2023

Antioxidants

View full text Add to dashboard Cite

Diabetic retinopathy is the retinal disease associated with hyperglycemia in patients who suffer from type 1 or type 2 diabetes. It includes maculopathy, involving the central retina and characterized by ischemia and/or edema, and peripheral retinopathy that progresses to a proliferative stage with neovascularization. Approximately 10% of the global population is estimated to suffer from diabetes, and around one in 5 of these individuals have diabetic retinopathy. One of the major effects of hyperglycemia is oxidative stress, the pathological state in which elevated production of reactive oxygen species damages tissues, cells, and macromolecules. The retina is relatively prone to oxidative stress due to its high metabolic activity. This review provides a summary of the role of oxidative stress in diabetic retinopathy, including a description of the retinal cell players and the molecular mechanisms. It discusses pathological processes, including the formation and effects of advanced glycation end-products, the impact of metabolic memory, and involvements of non-coding RNA. The opportunities for the therapeutic blockade of oxidative stress in diabetic retinopathy are also considered.

show abstract

Section: Diabetic Retinopathymentioning

confidence: 99%

Oxidative Stress and Its Regulation in Diabetic Retinopathy

Haydinger,

Oliver,

Ashander

et al. 2023

Antioxidants

View full text Add to dashboard Cite

show abstract

How does anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal photocoagulation (PRP) compare with PRP alone for adults with proliferative diabetic retinopathy?

Anderson

2023

Cochrane Clinical Answers

View full text Add to dashboard Cite

TNFSF15 inhibits progression of diabetic retinopathy by blocking pyroptosis via interacting with GSDME

Zhao,

Dai,

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

Diabetic retinopathy is a common microvascular complication of diabetes and a leading cause of blindness. Pyroptosis has emerged as a mechanism of cell death involved in diabetic retinopathy pathology. This study explored the role of GSDME-mediated pyroptosis and its regulation by TNFSF15 in diabetic retinopathy. We found GSDME was upregulated in the progression of diabetic retinopathy. High glucose promoted GSDME-induced pyroptosis in retinal endothelial cells and retinal pigment epithelial cells, attributed to the activation of caspase-3 which cleaves GSDME to generate the pyroptosis-executing N-terminal fragment. TNFSF15 was identified as a binding partner and inhibitor of GSDME-mediated pyroptosis. TNFSF15 expression was increased by high glucose but suppressed by the caspase-3 activator Raptinal. Moreover, TNFSF15 protein inhibited high glucose- and Raptinal-induced pyroptosis by interacting with GSDME in retinal cells. Collectively, our results demonstrate TNFSF15 inhibits diabetic retinopathy progression by blocking GSDME-dependent pyroptosis of retinal cells, suggesting the TNFSF15-GSDME interaction as a promising therapeutic target for diabetic retinopathy.

show abstract

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

Abstract: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Review)

Cited by 5 publications

References 174 publications

Oxidative Stress and Its Regulation in Diabetic Retinopathy

Oxidative Stress and Its Regulation in Diabetic Retinopathy

How does anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal photocoagulation (PRP) compare with PRP alone for adults with proliferative diabetic retinopathy?

TNFSF15 inhibits progression of diabetic retinopathy by blocking pyroptosis via interacting with GSDME

Contact Info

Product

Resources

About